The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study of LXH254 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.
 
Filip Janku
Stock and Other Ownership Interests - Trovagene
Consulting or Advisory Role - Deciphera; Foundation Medicine; Guardant Health; Immunome; Novartis; Sequenom; Trovagene
Research Funding - Agios; Astellas Pharma; BioMed Valley Discoveries; Deciphera; Fujifilm; Novartis; Piqur; Plexxikon; Roche; Symphony Evolution
Other Relationship - Bio-Rad
 
Gopa Iyer
No Relationships to Disclose
 
Anna Spreafico
Consulting or Advisory Role - Novartis
Research Funding - Bristol-Myers Squibb; Merck; Novartis
 
Noboru Yamamoto
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - Boehringer Ingelheim; Eisai; OncoTherapy Science; Otsuka; Takeda
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Quintiles (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Yung-Jue Bang
Consulting or Advisory Role - BeiGene; Samyang
Research Funding - AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Chong Kun Dang Pharmaceutical (Inst); Curis (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Green Cross (Inst); Lilly (Inst); Macrogenics (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Elena Elez
No Relationships to Disclose
 
Maja J. De Jonge
No Relationships to Disclose
 
Harry J.M. Groen
Consulting or Advisory Role - Abbvie (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Research Funding - Lilly (Inst); Roche (Inst)
 
Frederik Marmé
Honoraria - Amgen; AstraZeneca; Celgene; Eisai; Genomic Health; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Novartis; Roche
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Celgene; Eisai; Novartis; Pfizer; Roche
 
Kathrin Gollmer
Employment - Novartis
 
Annie St-Pierre
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Maritza Melendez
Employment - Novartis
 
Anna Mais
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Heidi Nauwelaerts
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Uz M. Stammberger
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Reinhard Dummer
Honoraria - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Sun Pharma; Takeda
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Sun Pharma; Takeda
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)